Earlier this week, Bioprocess International reported that Boehringer Ingelheim (BI) had decided to focus on launching its biosimilar products solely in the US market, and would forego launches in the European Union. The Center for Biosimilars® was able to independently confirm this report in an email with a representative from BI.
Earlier this week, Bioprocess International reported that Boehringer Ingelheim (BI) had decided to focus on launching its biosimilar products solely in the US market, and would forego launches in the European Union (EU). The Center for Biosimilars® was able to independently confirm this report in an email with a representative from BI.
“Our focus is on bringing Cyltezo (adalimumab-abdm) to the US market and we are committed to making it available to US patients as soon as possible, and certainly before 2023,” said the BI spokesperson.
“Boehringer Ingelheim believes the introduction of high-quality, lower-cost biosimilars is critical for both patients and the sustainability of the healthcare system. At this point in time, future biosimilars activities will be driven out of the US market, including partnership opportunities, while Boehringer Ingelheim is stopping development activities for the rest of the world,” said BI’s representative.
AbbVie, the developer of reference adalimumab sold as Humira, has entered into 6 patent litigation settlements with biosimilar adalimumab developers to date. Under the terms of each settlement, approved biosimilar adalimumab products were able to launch in the EU as recently as last month, while the US market will have to wait until 2023 to see any of those products enter the market.
BI alone has not settled its patent dispute with AbbVie, and the case over Cyltezo is moving forward in a Delaware District Court. In the suit, AbbVie asserted 74 patents covering its reference adalimumab product. BI is arguing that that AbbVie engaged in a “pattern of pursuing numerous overlapping and non-inventive patents for the purpose of developing a ‘patent thicket,’ using the patenting process itself as a means to seek to delay competition.”
To support its defense, BI asked the court to compel AbbVie to produce research and development documents dated outside the default 6-year period. Though the court rejected BI’s argument that the case was “unusual given the number of patents and claims at issue,” the court did order AbbVie to produce such documents in June 2018, finding that the information is relevant to the litigation.
BI is also investigating interchangeability of its product with the reference Humira.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.